| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/07/2014 | US8623393 Biomatrix structural containment and fixation systems and methods of use thereof |
| 01/07/2014 | US8623384 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of acute myelogenous leukemia |
| 01/07/2014 | US8623378 Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
| 01/07/2014 | US8623347 Antiviral drugs for treatment of arenavirus infection |
| 01/07/2014 | US8623338 Methionine-derived peptidomimetics and their use in the protection of mitochondria of cutaneous cells |
| 01/07/2014 | US8623336 Transparent xyloglucan/chitosan gel and a process for the preparation thereof |
| 01/07/2014 | US8623334 Topical anesthetic |
| 01/07/2014 | US8623331 Compressed chewing gum tablet |
| 01/07/2014 | US8623329 Method for the treatment of lung tumors |
| 01/07/2014 | CA2810334C Methods and compositions relating to coagulation assays |
| 01/07/2014 | CA2780732C Androgen receptor modulator and uses thereof |
| 01/07/2014 | CA2778886C N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| 01/07/2014 | CA2774961C Oral care compositions comprising increased bioavailable levels of quaternary ammonium antimicrobials |
| 01/07/2014 | CA2763775C Bisphosphonic acids for the treatment and prevention of osteoporosis |
| 01/07/2014 | CA2754681C Benzofuranyl derivatives used as glucokinase inhibitors |
| 01/07/2014 | CA2735934C Method of treatment of attention deficit/hyperactivity disorder (adhd) |
| 01/07/2014 | CA2733212C Arginine silicate inositol complex and use thereof |
| 01/07/2014 | CA2716838C Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same |
| 01/07/2014 | CA2712574C Polymorphic form of a [1,2,4]triazolo[4,3-a]pyridine derivative for treating inflammatory diseases |
| 01/07/2014 | CA2694504C (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof |
| 01/07/2014 | CA2680018C Combination medicaments for treating bacterial infections |
| 01/07/2014 | CA2664915C Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent |
| 01/07/2014 | CA2660424C Sulfonamide compound or salt thereof |
| 01/07/2014 | CA2657107C Human protein tyrosine phosphatase inhibitors and methods of use |
| 01/07/2014 | CA2636618C Oral s-adenosylmethionine compositions |
| 01/07/2014 | CA2635903C Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity |
| 01/07/2014 | CA2635813C Urea derivatives as kinase inhibitors and methods of use thereof |
| 01/07/2014 | CA2629988C Pharmaceutical composition for the treatment of acute disorders |
| 01/07/2014 | CA2629327C Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease |
| 01/07/2014 | CA2624310C Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide |
| 01/07/2014 | CA2617422C Fluid, method, and device for eradication of pigmentation and scar tissue |
| 01/07/2014 | CA2611909C Composition for treatment of corneal disease |
| 01/07/2014 | CA2611438C Cyclic anilino-pyridinotriazines |
| 01/07/2014 | CA2609875C Crystalline solid forms of tigecycline and methods of preparing same |
| 01/07/2014 | CA2606530C Phycotoxins and uses thereof |
| 01/07/2014 | CA2602800C Pyrazolopyridines and analogs thereof |
| 01/07/2014 | CA2594187C Method for producing probiotically derived compounds |
| 01/07/2014 | CA2570999C Compounds, compositions and methods |
| 01/07/2014 | CA2570614C Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
| 01/07/2014 | CA2566625C Thiazole compound and use thereof |
| 01/07/2014 | CA2563117C Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor |
| 01/07/2014 | CA2560922C Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions |
| 01/07/2014 | CA2542504C Lipids containing omega-3 and omega-6 fatty acids |
| 01/07/2014 | CA2514650C Use of edible acids in fast-dispersing pharmaceutical solid dosage forms |
| 01/07/2014 | CA2497216C Local vascular delivery of cladribine in combination with rapamycin to prevent restenosis following vascular injury |
| 01/07/2014 | CA2453967C Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/03/2014 | WO2014005150A1 Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof |
| 01/03/2014 | WO2014005129A1 Cyanoguanidines and their use as antiviral agents |
| 01/03/2014 | WO2014005122A2 Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration |
| 01/03/2014 | WO2014005089A2 Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances |
| 01/03/2014 | WO2014005032A1 Racecadotril lipid compositions |
| 01/03/2014 | WO2014005021A1 Racecadotril liquid compositions |
| 01/03/2014 | WO2014005013A2 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| 01/03/2014 | WO2014005010A2 Methods of treating breast cancer with gemcitabine therapy |
| 01/03/2014 | WO2014005008A2 Short-term surrogate test for investigative drugs |
| 01/03/2014 | WO2014004993A2 Methods of reducing ldl-p |
| 01/03/2014 | WO2014004951A1 Novel fatty acid-salicylate conjugates with enhanced therapeutic properties |
| 01/03/2014 | WO2014004902A2 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof |
| 01/03/2014 | WO2014004895A1 Stable formulations for parenteral injection of small molecule drugs |
| 01/03/2014 | WO2014004863A2 Compounds, compositions, and therapeutic uses thereof |
| 01/03/2014 | WO2014004861A2 Methods of treating pediatric metabolic syndrome |
| 01/03/2014 | WO2014004854A1 Induction of estrogen receptor beta by cholesterol biosynthesis inhibitors and methods of treatment of cancer |
| 01/03/2014 | WO2014004733A1 Composition for lupus nephritis and methods of making and using the same |
| 01/03/2014 | WO2014004707A1 Formulations comprising ibrutinib |
| 01/03/2014 | WO2014004676A1 Use of faah inhibitors as neuroprotective agents in the cns |
| 01/03/2014 | WO2014004674A2 Methods for treating hcv |
| 01/03/2014 | WO2014004664A2 Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives |
| 01/03/2014 | WO2014004647A1 A nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2 |
| 01/03/2014 | WO2014004543A1 Combination cancer therapy using bisphosphonates and anti-egfr agents |
| 01/03/2014 | WO2014004470A1 Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using pi3 kinase inhibitors |
| 01/03/2014 | WO2014004417A1 Nicotinic receptor non-competitive antagonists |
| 01/03/2014 | WO2014004416A1 Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
| 01/03/2014 | WO2014004376A2 Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| 01/03/2014 | WO2014004339A2 Method for stimulating cellular beta defensins |
| 01/03/2014 | WO2014004309A1 Accelerators for two part curable compositions |
| 01/03/2014 | WO2014004297A1 Accelerators for curable compositions |
| 01/03/2014 | WO2014004230A1 Dimethyl-benzoic acid compounds |
| 01/03/2014 | WO2014004229A1 Phenoxyethyl piperidine compounds |
| 01/03/2014 | WO2014004126A1 Treating postoperative nausea and vomiting |
| 01/03/2014 | WO2014004054A1 Compositions and methods for treating cancer with aberrant lipogenic signaling |
| 01/03/2014 | WO2014003849A1 USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM |
| 01/03/2014 | WO2014003834A1 Method of stably treating incontinence using a bulking agent |
| 01/03/2014 | WO2014003808A1 Method of extracting kaempferol-based antioxidants from solenostemma arghel |
| 01/03/2014 | WO2014003694A1 Synthesis of thiosemicarbazides and triazoles derived from etodolac |
| 01/03/2014 | WO2014003693A1 Etodolac derivatives as hcv ns5b polymerase inhibitors |
| 01/03/2014 | WO2014003678A1 Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
| 01/03/2014 | WO2014003677A1 Pharmaceutical compositions comprising solid dispersion particles containing tadalafil |
| 01/03/2014 | WO2014003483A1 Fused pyrimidine derivatives having inhibitory activity on fms kinases |
| 01/03/2014 | WO2014003454A1 Oral dosage form product of clopidogrel hydrogen sulfate with improved stability |
| 01/03/2014 | WO2014003424A1 Novel rebamipide prodrug, method for producing same, and usage thereof |
| 01/03/2014 | WO2014003411A1 Method for preparing α-crystalline form of imatinib mesylate |
| 01/03/2014 | WO2014003400A1 Aripiprazole-organic acid cocrystal, preparation or composition containing same, and preparation method therefor |
| 01/03/2014 | WO2014003371A1 Immediate-release and sustained-release pharmaceutical composition comprising acebrophylline |
| 01/03/2014 | WO2014003307A1 Artificial saliva composition comprising hyaluronic acid |
| 01/03/2014 | WO2014003305A1 Pharmaceutical composition containing fimasartan and hydrochlorothiazide |
| 01/03/2014 | WO2014003224A1 Compositions for whitening skin comprising madecassoside |
| 01/03/2014 | WO2014003158A1 Indole derivative or salt thereof |
| 01/03/2014 | WO2014003155A1 Pharmaceutical composition containing compound having thrombopoietin receptor agonistic activity |
| 01/03/2014 | WO2014003154A1 Agent for preventing deterioration in vascular endothelial function or improving vascular endothelial function |
| 01/03/2014 | WO2014003153A1 Substituted amide compound |